Position in FTRE
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$4,554,519
-$3,209,725 QoQ
Shares Held
261,754
-74.5% QoQ
Ownership
0.275%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#50
of 334 holders
Holding Since
Sep 2023
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NORDEA INVESTMENT MANAGEMENT AB holds $503,679,873 across 20 Biotechnology names. FTRE ranks #15 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
363,479 | $226,643,694 | |
| 2 | RPRX |
Royalty Pharma plc
|
2,576,772 | $144,479,604 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
284,175 | $23,163,103 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
49,943 | $15,786,482 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,496 | $15,148,278 | |
| 6 | EXEL |
Exelixis, Inc.
|
210,314 | $11,443,184 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
26,913 | $8,101,620 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
64,964 | $7,963,286 |
All Filings in FTRE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,554,519 | 261,754 | Shares | Defined | 2026-08-05 | |
| 2025-03-31 | $7,764,244 | 1,028,377 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $28,666,913 | 1,537,100 | Shares | Sole | 2025-01-06 | |
| 2024-09-30 | $32,926,320 | 1,646,316 | Shares | Sole | 2024-11-05 | |
| 2024-06-30 | $56,239,667 | 2,409,583 | Shares | Defined | 2024-08-08 | |
| 2024-03-31 | $39,426,110 | 982,215 | Shares | Sole | 2024-05-02 | |
| 2023-12-31 | $745,115 | 21,350 | Shares | Sole | 2024-01-10 | |
| 2023-09-30 | $610,853 | 21,366 | Shares | Sole | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||